Target Name: IER3
NCBI ID: G8870
Review Report on IER3 Target / Biomarker Content of Review Report on IER3 Target / Biomarker
IER3
Other Name(s): IEX-1L | Radiation-inducible immediate-early gene IEX-1 | DIF-2 | differentiation-dependent gene 2 protein | immediate early response 3 | PACAP-responsive gene 1 protein | anti-death protein | protein DIF-2 | Immediately early gene X-1 | immediate early protein GLY96 | IEX1 | Immediate early protein GLY96 | immediate early response 3 protein | Protein PRG1 | gly96, mouse, homolog of | Differentiation-dependent gene 2 protein | OTTHUMP00000029400 | Immediate early response 3 protein | DIF2 | IEX-1 | Anti-death protein | PACAP-responsive gene 1 | IEX1_HUMAN | expressed in pancreatic carcinoma | Differentiation-dependent gene 2 | Protein DIF-2 | GLY96 | immediately early gene X-1 | PRG1 | Immediate early response 3 | Expressed in pancreatic carcinoma

IER3: A Protein Involved in Cellular Processes That Affect Cell Survival and Proliferation

IER3 (IEX-1L) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the IEX family of transmembrane proteins, which are characterized by their ability to form a continuous transmembrane region that is involved in various signaling pathways.

One of the most significant functions of IER3 is its role in the regulation of ion channels, which are responsible for the flow of electrical current through the cell membrane. IER3 is involved in the regulation of the delayed rectifier channels, which are important for the maintenance of the resting membrane potential of the heart.

In addition to its role in ion channel regulation, IER3 is also involved in the regulation of various signaling pathways that are involved in cell growth, differentiation, and survival. For example, IER3 has been shown to be involved in the regulation of the TGF-β pathway, which is involved in the development and maintenance of tissues such as muscles, bones, and organs.

IER3 is also involved in the regulation of the Wnt pathway, which is involved in the development and maintenance of tissues that are involved in the development of cancers. The Wnt pathway is a critical regulator of cell growth and differentiation, and IER3 is shown to be involved in the regulation of its activity.

In addition to its involvement in ion channel and signaling pathway regulation, IER3 is also involved in the regulation of various cellular processes that are important for cell survival. For example, IER3 is involved in the regulation of cell adhesion, which is important for the maintenance of tissue structure and function.

IER3 is also involved in the regulation of cellular signaling pathways that are important for cell survival and proliferation. For example, IER3 has been shown to be involved in the regulation of the PI3K/AKT signaling pathway, which is involved in the production of signaling molecules that are important for the survival and proliferation of cells.

In conclusion, IER3 is a protein that is involved in a wide range of cellular processes that are important for cell survival and proliferation. Its role in the regulation of ion channels, signaling pathways, and cellular processes that are important for cell survival and proliferation makes IER3 an attractive potential drug target. Further research is needed to fully understand the role of IER3 in these processes and to develop effective therapies that target this protein.

Protein Name: Immediate Early Response 3

Functions: May play a role in the ERK signaling pathway by inhibiting the dephosphorylation of ERK by phosphatase PP2A-PPP2R5C holoenzyme. Acts also as an ERK downstream effector mediating survival. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment

The "IER3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IER3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

IER3-AS1 | IER3IP1 | IER5 | IER5L | IER5L-AS1 | IFFO1 | IFFO2 | IFI16 | IFI27 | IFI27L1 | IFI27L2 | IFI30 | IFI35 | IFI44 | IFI44L | IFI6 | IFIH1 | IFIT1 | IFIT1B | IFIT2 | IFIT3 | IFIT5 | IFITM1 | IFITM10 | IFITM2 | IFITM3 | IFITM3P2 | IFITM3P7 | IFITM4P | IFITM5 | IFITM8P | IFITM9P | IFNA1 | IFNA10 | IFNA12P | IFNA13 | IFNA14 | IFNA16 | IFNA17 | IFNA2 | IFNA21 | IFNA22P | IFNA4 | IFNA5 | IFNA6 | IFNA7 | IFNA8 | IFNAR1 | IFNAR2 | IFNB1 | IFNE | IFNG | IFNG-AS1 | IFNGR1 | IFNGR2 | IFNK | IFNL1 | IFNL2 | IFNL3 | IFNL4 | IFNLR1 | IFNW1 | IFNWP15 | IFNWP19 | IFRD1 | IFRD2 | IFT122 | IFT122P3 | IFT140 | IFT172 | IFT20 | IFT22 | IFT27 | IFT43 | IFT46 | IFT52 | IFT57 | IFT74 | IFT80 | IFT81 | IFT88 | IFTAP | IGBP1 | IGBP1P1 | IGDCC3 | IGDCC4 | IgE Receptors | IGF1 | IGF1R | IGF2 | IGF2-AS | IGF2BP1 | IGF2BP2 | IGF2BP2-AS1 | IGF2BP3 | IGF2R | IGFALS | IGFBP-AS1 | IGFBP1 | IGFBP2